Osoyoos Cannabis Inc. (the “Company”) is pleased to provide an update on recent events which will have a material impact on its future operations.

On October 31, 2018, following shareholder meetings of both Osoyoos Cannabis Inc. (“OSO”) and LKP Solutions Inc. (“LKP”), the transactions contemplated by the Business Combination Agreement (the “BCA”) disclosed on July 17, 2018 was completed. The transactions contemplated by the BCA were effected pursuant to the Business Corporations Act (British Columbia) as a ‘three-cornered amalgamation’ among LKP, OSO and 1160546 B.C. Ltd. (“1160546”). 1160546 is a wholly-owned subsidiary of LKP which was incorporated for the purposes of the BCA. For further details regarding the BCA, please refer to LKP’s Management Information Circular dated September 12, 2018, which may be viewed under the Company’s profile at: https://www.sedar.com.


Pursuant to the BCA, LKP consolidated its common shares on a 2.5:1 basis immediately prior to the amalgamation of OSO and 1160546. The remaining entity, 1160546, continued as a 100% subsidiary of LKP. On November 1, 2018, LKP changed its name to Osoyoos Cannabis Inc., and the former OSO shareholders exchanged their shares on a 1:1 basis for shares of LKP.

The new directors of the Company are the former directors of OSO, consisting of: Mr. Gerry Goldberg (CEO), Mr. John McMahon (independent), Mr. Ernie Eves (independent), Mr. Roger Dent (independent) and Ms. Sarah Lee Irwin (independent).

Proposed Operations

The Company will be in the business of processing raw cannabis to produce concentrated extracts which may be consumed directly or infused into a variety of recreational or medicinal products. Extracts may be packaged and sold as the Company’s own branded products, or be sold to others. The Company may also ‘toll’ process raw cannabis supplied by others for a negotiated fee.

In March 2017, Bare Root Production Osoyoos Inc. (now the 100% owned subsidiary of 1160546) made an application to Health Canada under the ACMPR for the cultivation of cannabis; however, in response to early industry trends which were emerging during the application process, the decision was made to instead focus initially on the value-added extraction sector of the emerging industry.

On October 3, 2018, OSO retained Eurofins Experchem Laboratories Inc., a leading cannabis industry consulting agency, to assist it with the preparation and submission of an amendment to its original application. This work is in process and the Company will submit an application for licensing as a ‘standard processor’ of cannabis under section 17 of the Cannabis Regulations under the Cannabis Act (Canada). This application may be amended at a later stage to include direct sales, cultivation, analytical testing and/or research.

CSE Listing Application

The Company has submitted an application to list its common shares on the Canadian Securities Exchange and the application is in the review stage. There is no assurance that the securities of the Company will be listed.

ON BEHALF OF THE BOARD

OSOYOOS CANNABIS INC.

“GERRY GOLDBERG”
CEO

For further information contact:
Gerry Goldberg
gerrygoldbergcpa@gmail.com
(416) 460-3000

DISCLAIMER & READER ADVISORY

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the Company to become licensed in Canada to produce and sell cannabis extracts. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain the necessary corporate, regulatory and other third-party approvals; licensing and other risks associated with Cannabis Act (Canada) operations. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

Source: www.newsfilecorp.com

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less